Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions.
Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias or panic disorders, GAD is not limited to particular triggers and can encompass a broad range of concerns. The persistent nature of the anxiety can significantly impact daily functioning and overall well-being. Treatment often involves a combination of therapy, such as cognitive-behavioral therapy (CBT), and medication to manage symptoms and improve quality of life.
The Generalized Anxiety Disorder (GAD) drugs in development market research report provide comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Generalized Anxiety Disorder (GAD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Generalized Anxiety Disorder (GAD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Generalized Anxiety Disorder (GAD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Generalized Anxiety Disorder (GAD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Generalized Anxiety Disorder (GAD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncArtelo Biosciences Inc
Avineuro Pharmaceuticals Inc
Cybin Inc
Diamond Therapeutics Inc
Engrail Therapeutics Inc
GABA Therapeutics Inc
Gerbera Therapeutics Ltd
Incannex Healthcare Ltd
Institute of Materia Medica
Chinese Academy of Medical Sciences & Peking Union Medical College
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Johnson & Johnson
Luye Pharma Group Ltd
Mind Medicine MindMed Inc
Nubiyota LLC
NW PharmaTech Ltd
Ophidion Inc
Protagenic Therapeutics Inc
Psy Therapeutics Inc
PSYLO Pty Ltd
Sage Therapeutics Inc
Seed Health Inc
Sumitomo Pharma America Inc
Sun Pharmaceutical Industries Ltd
Viatris Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Generalized Anxiety Disorder (GAD) reports